美股
Lead report
Aethlon Tumor Trial Expands to 3-6 Patients: Hemopurifier Clinical Progress Analysis
Aethlon Medical announces expansion of Hemopurifier tumor trial Cohort 3 to 3-6 patients, focusing on exosome clearance combined with immunotherapy. This article analyzes the technology, financial background, competitive landscape, and key investor considerations.
